Introduction of an Automated System for the Diagnosis and Quantification of Hepatitis B and Hepatitis C Viruses

Cabezas-Fernández, M.T.; Cabeza-Barrera, MI

doi:10.2174/1874357901206010122

Cited by 11 publications

(9 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lower limit of the detection is recommended to be at least 10 IU/mL to determine the viral rebound early. Also, the method must be able to quantitatively detect all the HBV genotypes in equal accuracy [9]. In this study, a high correlation was seen between the two test methods in terms of accuracy and quantification (Figure 1), but differences over one log were observed in nine of the patients (7.6%).…”

Section: Discussionmentioning

confidence: 52%

Comparison of a novel real-time PCR method (RTA) and Artus RG for the quantification of HBV DNA and HCV RNA

Aydoğan

Acikgoz

Gözalan

et al. 2017

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: The purpose of this study was to evaluate and compare two manual isolation and real-time (RT) polymerase chain reaction (PCR) kits (RTA RT-PCR with RTA isolation kit and Artus RG RT-PCR with QIAamp isolation kit) for molecular diagnosis of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. Methodology: The study was conducted on 121 and 54 clinical samples for the detection of HBV DNA and HCV RNA, respectively, with an additional 8 HCV RNA external quality control samples. Results: Though a high correlation was observed between the two kits for the HBV DNA (r = 0.955, p = 0.001) and HCV RNA quantifications (r = 0.828, p = 0.001), discordant results were found in nine of the HBV DNA and in six of the HCV RNA samples. The mean difference between the two systems was found to be 0.4 log IU/mL in Quality Control for Molecular Diagnostics (QCMD) HCV RNA samples by BlandAltman analysis. Conclusions: Although there was a high correlation between HBV DNA and HCV RNA tests according to the results of the study, the RTA system requires improvement for the determination of HCV RNA.

show abstract

Section: Discussionmentioning

confidence: 52%

Comparison of a novel real-time PCR method (RTA) and Artus RG for the quantification of HBV DNA and HCV RNA

Aydoğan

Acikgoz

Gözalan

et al. 2017

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…The incubation time and pump rates were modified to determine the optimized assay program with duration less than 15 minutes, which is faster than any other comparable commercial test system. 9 The electrochemical detection method single electrode redox cycling and the related signal evaluation achieved sensitive and reproducible results (Figure 4). The microtiter plate ELISA described previously, based on 39 HCV-negative and 32 HCV-positive serum samples, was repeated with the point-of-care biochip system for comparability tests.…”

Section: Analysis On Electrical Biochipsmentioning

confidence: 91%

“…In our comparability measurements, 2 µL of each serum sample was pipetted into the collector, whereas other commercially available EIA-based systems require a sample volume of 20-100 µL. 9 In practical use, pricking the fingertip with a sterile needle allows a 2 µL sample to be collected by capillary transfer.…”

Section: Analysis On Electrical Biochipsmentioning

confidence: 99%

“…8 Since the discovery of HCV in 1989, four generations of serological test systems have improved the sensitivity and specificity of EIA-based HCV diagnosis. 9 Current thirdgeneration assays include different HCV proteins, such as Core (c22-3), NS3 (c33p), NS4 (c100-3), and NS5, thus achieving an average sensitivity of 98%. 10 One major drawback of these test systems is the number of false-negative results, reflecting late Ab responses, and false-positive results caused by other issues.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rapid detection of different human anti-HCV immunoglobulins on electrical biochips

Blohm¹,

Püttmann²,

Holz³

et al. 2014

ANTI

View full text Add to dashboard Cite

The detection of hepatitis C virus (HCV) in the blood of patients is currently based on immunological assays (enzyme-linked immunosorbent assay [ELISA] and recombinant immunoblot assay) that use different HCV epitopes to detect anti-HCV antibodies, and these tests usually require laboratories and trained personnel. The ELISA-based systems are also time consuming. Portable diagnostic devices offering rapid test results would therefore be advantageous in the field of medical care. To facilitate the fast and reliable diagnosis of HCV, we used a miniaturized automated system based on a cartridge with an integrated electrical biochip for the decentralized detection of anti-HCV antibodies against the Core, NS3, and NS4A proteins. This system allows the detection of virus-specific antibodies in 2 µL of serum or whole blood within 15 minutes using an ELISA directly on a gold electrode array containing HCV proteins as the capture antigen. The sensitivity of this system is comparable with standard microtiter plate ELISAs, but the duration of the novel assay is 5%–6% that of standard ELISAs

show abstract

“…Both the hepatitis B surface antigen (HBsAg) and the hepatitis C virus IgG (anti-HCV) were determined using Maglumi 1000 (Shenzhen New Industries Biomedical Engineering Co., Ltd, Shenzhen, China), a fully automated chemiluminescence immunoassay, according to the manufacturer's instructions. 16 The HBsAg kit had a sensitivity of <1 index/mL and a specificity of 100%, while the HCV IgG kit had a sensitivity of 2 U/mL and a specificity of 100%. HIV-1 viral load was determined using the Abbott m2000rt System (Abbott Molecular Inc., Des Plaines, Illinois, USA) with automated sample extraction, amplification, and detection, according to the manufacturer's instructions.…”

Section: Data Collection and Laboratory Investigationsmentioning

confidence: 93%

Prevalence and Factors Associated With Hepatitis B and C Co-Infection Among HIV-1-Infected Patients in Kenya

Maina

Nyerere

Gicho

et al. 2017

EAHRJ

View full text Add to dashboard Cite

Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are among the most chronic viral infections worldwide.Co-infections with HBV and HCV have become increasingly common among people living with HIV, resulting in a growing public health concern. The primary aim of our study was to determine the prevalence of HBV and HCV and their associated factors among HIV-1-infected patients attending the Ngong Sub-County Hospital comprehensive care clinic.Methods: After providing consent, a 5 mL blood sample was collected from each study participant visiting the comprehensive care clinic. The blood was screened for hepatitis B surface antigen and HCV antibodies using chemiluminescence immunoassay test according to the manufacturer's instructions. The CD4 T-cell counts were determined using FACSCalibre machine, while HIV-1 viral load was determined using the Abbott m2000rt System according to the manufacturer's instructions. A questionnaire was used to collect sociodemographic information and data on factors associated with HBV and HCV co-infections.Results: One hundred and ninety HIV-1-infected patients participated in this study: 150 (78.9%) women and 40 (21.1%) men.In the overall study population, the prevalence of HBV co-infection was 5.8% (95% CI, 2.6%-8.9%) and of HCV coinfection was 4.2% (95% CI, 1.6%-7.4%). However, no individual was co-infected with all 3 viruses. HCV was associated with antiretroviral treatment (OR 0.2; 95% CI, 0.0-0.8; P=.036), while HBV showed a significant association with condom usage (OR 0.3; 95% CI, 0.1-0.9; P=.039) and median viral load.

show abstract

Introduction of an Automated System for the Diagnosis and Quantification of Hepatitis B and Hepatitis C Viruses

Cited by 11 publications

References 96 publications

Comparison of a novel real-time PCR method (RTA) and Artus RG for the quantification of HBV DNA and HCV RNA

Comparison of a novel real-time PCR method (RTA) and Artus RG for the quantification of HBV DNA and HCV RNA

Rapid detection of different human anti-HCV immunoglobulins on electrical biochips

Prevalence and Factors Associated With Hepatitis B and C Co-Infection Among HIV-1-Infected Patients in Kenya

Contact Info

Product

Resources

About